KENNEDY CAPITAL MANAGEMENT LLC
Position in GLUE — Monte Rosa Therapeutics, Inc.
CIK 884589
ST LOUIS, MO
Position in GLUE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$9,813,801
+$9,287,780 QoQ
Shares Held
405,529
+1168.2% QoQ
Ownership
0.475%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#40
of 193 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 98%
Shared 0%
None 2%
Common Shares in GLUE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026KENNEDY CAPITAL MANAGEMENT LLC holds $451,584,893 across 62 Biotechnology names. GLUE ranks #18 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
544,994 | $42,656,680 | |
| 2 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
193,215 | $21,452,661 | |
| 3 | NRIX |
Nurix Therapeutics, Inc.
|
724,508 | $17,576,564 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
201,979 | $17,562,074 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
134,019 | $16,428,049 | |
| 6 | MGTX |
MeiraGTx Holdings plc
|
1,105,421 | $14,934,237 | |
| 7 | ADMA |
Adma Biologics, Inc.
|
1,755,152 | $14,690,622 | |
| 8 | NAMS |
NewAmsterdam Pharma Co N.V.
|
421,374 | $14,280,364 |
All Filings in GLUE
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,813,801 | 405,529 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $526,021 | 31,977 | Shares | Sole | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||